Cambridge Investment Research Advisors
SUPN icon

Cambridge Investment Research Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,769
Closed -$336K – 4063
2025
Q4 		$336K Buy
+6,769
New +$329K ﹤0.01% 3088
2018
Q4 		– Sell
-7,221
Closed -$364K – 2275
2018
Q3 		$364K Buy
+7,221
New +$357K ﹤0.01% 1660

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's SUPN Position: Q1 2026 in Review

Cambridge Investment Research Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 6,769 shares — an estimated $336K sold.

Cambridge Investment Research Advisors first reported a position in SUPN in Q3 2018 and held it in 2 quarters. The position peaked at $364K in Q3 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Cambridge Investment Research Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,769 Supernus Pharmaceuticals shares in Q1 2026, an estimated $336K.
  • Cambridge Investment Research Advisors first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Supernus Pharmaceuticals position peaked at $364K in Q3 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.